Onconova (NASDAQ: ONTX) was downgraded by Zacks.com  from a “buy” rating to a “hold” score in a research note provided to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on finding and creating little molecule medication prospects to deal with cancer. The Firm‘s products under different stages of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts also just recently discussed the business. Noble Financial reissued a “acquire” rating and also issued a $11.00 price goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “buy” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving typical rate of $2.90 and also a two-hundred day moving average cost of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, topping experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and an adverse net margin of 8,294.27%. The company had revenue of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. Throughout the very same quarter in the prior year, the firm posted ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the current year.

A variety of hedge funds have lately bought and sold shares of ONTX. GSA Capital Allies LLP got a brand-new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Capital Management LP purchased a new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and various other institutional financiers possess 13.36% of the firm’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which participates in the identification as well as advancement of oncology therapeutics. It focuses on uncovering as well as creating small particle medicine candidates to treat cancer. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more details about research offerings from Zacks Investment Research, go to Zacks.com.

This instantaneous news alert was produced by narrative scientific research technology and also financial information from Market in order to give visitors with the fastest and most precise coverage. This tale was examined by Market’s content team prior to magazine. 



Before you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market tracks Wall Street’s top-rated as well as ideal carrying out research experts and also the stocks they suggest to their customers every day. Market has recognized the 5 stocks that cover experts are silently whispering to their clients to get currently before the more comprehensive market catches on … and Onconova Therapeutics had not been on the list.

While Onconova Therapeutics presently has a “Buy” rating amongst experts, top-rated experts think these 5 stocks are better acquires.